Mielóma multiplex: vizsgálatok itt: Kína
204 trials · From ClinicalTrials.gov, checked 2026. november 16.. Ask the study team whether a trial fits you.
- 1/2. fázisTaking peopleASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM)
- Where
- Tianjin
- Életkor
- 18 év to 70 év
- People
- 20
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT05632380 - 2. fázisTaking peopleMRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly Diagnosed Multiple Myeloma
- Where
- Tianjin
- Életkor
- 18 év and over
- People
- 20
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07409454 - No phaseTaking peopleLongitudinal Data Registry of Plasma Cell Dyscrasia
- Where
- Shanghai
- Életkor
- 19 év to 99 év
- People
- 2000
- Run by
- Shanghai Zhongshan Hospital
See details and how to joinNCT06760052 - 2. fázisTaking peopleA Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 30
- Run by
- Shanghai Zhongshan Hospital
See details and how to joinNCT07638683 - 1. fázisTaking peopleA Clinical Study of SHR-5421 in Patients With Multiple Myeloma
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 97
- Run by
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
See details and how to joinNCT07652281 - 1. fázisNot yet taking people in KínaA Study of KIV-318 Injection in Patients With BCMA-Positive Relapsed/Refractory Multiple Myeloma
- Where
- Tianjin
- Életkor
- 18 év to 70 év
- People
- 30
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07726160 - No phaseTaking peopleBCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma
- Where
- Tianjin
- Életkor
- 18 év to 78 év
- People
- 20
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT06745687 - Korai 1. fázisTaking peopleA Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019A in Patients With Relapsed/Refractory Multiple Myeloma.
- Where
- Wuhan
- Életkor
- 18 év and over
- People
- 24
- Run by
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT07429721 - Korai 1. fázisTaking peopleValue of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases
- Where
- Fuzhou
- Életkor
- 18 év to 80 év
- People
- 50
- Run by
- First Affiliated Hospital of Fujian Medical University
See details and how to joinNCT04504526 - Korai 1. fázisTaking peopleAn Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies
- Where
- Wuhan
- Életkor
- 18 év to 75 év
- People
- 40
- Run by
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT07101705 - 1. fázisTaking peopleIn Vivo PICX CAR-T Therapy for R/R Multiple Myeloma
- Where
- Kunming
- Életkor
- 18 év and over
- People
- 15
- Run by
- Chongqing Precision Biotech Co., Ltd
See details and how to joinNCT07715630 - 4. fázisNot yet taking people in KínaA Single-center, Prospective, Single-arm Clinical Study Exploring the Treatment of Newly Diagnosed Multiple Myeloma Patients With t(11;14) Suitable for Transplantation Using the SonKRd Regimen
- Where
- Suzhou
- Életkor
- 18 év and over
- People
- 20
- Run by
- The First Affiliated Hospital of Soochow University
See details and how to joinNCT07709884 - 3. fázisTaking peopleA Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
- Where
- Beijing, Guangzhou, Hangzhou, Luoyang, Suzhou, Taiyuan, Tianjin, Wuhan, Xi'an, Zhengzhou
- Életkor
- 18 év to 75 év
- People
- 360
- Run by
- Hangzhou Sumgen Biotech Co., Ltd.
See details and how to joinNCT06508983 - 1/2. fázisTaking peopleTo Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma
- Where
- Hangzhou, Suzhou, Xi'an, Zhengzhou
- Életkor
- 18 év to 80 év
- People
- 40
- Run by
- Hangzhou Sumgen Biotech Co., Ltd.
See details and how to joinNCT07454187 - 1/2. fázisNot yet taking people in KínaSonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic Stratification
- Where
- Tianjin
- Életkor
- 18 év to 70 év
- People
- 50
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07687004 - 4. fázisTaking peopleElranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
- Where
- Beijing, Guangzhou, Hangzhou, Jinan
- Életkor
- 18 év and over
- People
- 80 worldwide
- Run by
- Pfizer
See details and how to joinNCT06057402 · EU 2023-505200-33-00 - No phaseTaking peopleIsatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients
- Where
- Beijing, Chengdu, Guangzhou, Harbin, Kunming, Naning, Nanjing, Nantong, Shanghai, Shenzhen, Wuhan, Xi’an, Zhengzhou
- Életkor
- 18 év and over
- People
- 333
- Run by
- Shanghai Zhongshan Hospital
See details and how to joinNCT07663253 - 2/3. fázisTaking people68Ga-BCMA PET/CT in Multiple Myeloma
- Where
- Beijing, Jilin City, Shijiazhuang
- Életkor
- 18 év to 80 év
- People
- 300
- Run by
- Peking University First Hospital
See details and how to joinNCT07319897 - 1. fázisTaking peopleSafety and Efficacy of RN1201 Injection as First-Line Treatment for Newly Diagnosed Multiple Myeloma
- Where
- Suzhou
- Életkor
- 18 év to 70 év
- People
- 18
- Run by
- The First Affiliated Hospital of Soochow University
See details and how to joinNCT07652138 - Korai 1. fázisNot yet taking people in KínaSafety and Efficacy of RN9101 in the Treatment of Relapsed/Refractory Multiple Myeloma
- Where
- Nanjing
- Életkor
- 18 év and over
- People
- 19
- Run by
- The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT07628595 - 2. fázisTaking peoplePhase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma
- Where
- Tianjin
- Életkor
- 18 év and over
- People
- 160
- Run by
- Qilu Pharmaceutical Co., Ltd.
See details and how to joinNCT07018050 - 1. fázisTaking peopleA Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
- Where
- Chengdu
- Életkor
- 18 év and over
- People
- 33
- Run by
- Sichuan Baili Pharmaceutical Co., Ltd.
See details and how to joinNCT07255898 - 1. fázisTaking peopleA Phase I Study of SHR-3836 in Patients With Multiple Myeloma
- Where
- Suzhou
- Életkor
- 18 év and over
- People
- 99
- Run by
- Shanghai Hengrui Pharmaceutical Co., Ltd.
See details and how to joinNCT07490613 - 3. fázisTaking peopleA Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma
- Where
- Tianjin
- Életkor
- 18 év and over
- People
- 228
- Run by
- Qilu Pharmaceutical Co., Ltd.
See details and how to joinNCT07138209 - 3. fázisTaking peopleA Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma
- Where
- Tianjing
- Életkor
- 18 év and over
- People
- 261
- Run by
- Shandong New Time Pharmaceutical Co., LTD
See details and how to joinNCT07579234